Clinical trial
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
NCT00392769 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00392769 |
|---|---|
| Title | Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer |
| Official title | Phase II Study of Cetuximab (Erbitux) in Patients With Progressive or Recurrent Endometrial Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 33 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 26, 2006 |
| Last update posted | Sep 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: